Nasdaq issues conditional compliance notice to Medicus Pharma
Medicus Pharma received a Nasdaq conditional compliance notice on November 18, 2026, lifting the deficiency under the $35 million Market Value of Listed Securities standard because it demonstrated compliance with the alternative $2.5 million minimum shareholders' equity standard. Continued compliance is conditioned on evidencing shareholders' equity compliance in the next periodic report for the period ending December 31, 2026; failure to do so could result in delisting from Nasdaq.
Key takeaways
Nasdaq issued a conditional compliance notice to Medicus Pharma on November 18, 2026.
The prior deficiency involved the company's Market Value of Listed Securities falling below $35 million for 30 consecutive business days.
Nasdaq lifted that deficiency after the company demonstrated compliance with the alternative $2.5 million minimum shareholders' equity requirement under Listing Rule 5550(b)(1).
The company attributed its ability to satisfy the alternative standard to the completion of transactions described in its November 16, 2026 Form 8-K.
The company must evidence continued shareholders' equity compliance in its next periodic report for the period ending December 31, 2026.
If the company does not evidence compliance in that report, it may be subject to delisting from Nasdaq.
The company stated that there is no assurance it will maintain compliance with the shareholders' equity requirement or Nasdaq's other continued listing requirements.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow MDCX in real time
Get material earnings, filing, IR, and earnings-call alerts by email.